Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer.
Reads0
Chats0
TLDR
Comparing the outcomes from three prospective multicenter studies investigating the use of CTC to monitor patients undergoing treatment for metastatic breast, colorectal, or prostate cancer is compared and the CTC definition used in these studies is reviewed.Abstract:
The increasing number of treatment options for patients with metastatic carcinomas has created a concomitant need for new methods to monitor their use. Ideally, these modalities would be noninvasive, be independent of treatment, and provide quantitative real-time analysis of tumor activity in a variety of carcinomas. Assessment of circulating tumor cells (CTCs) shed into the blood during metastasis may satisfy this need. We developed the CellSearch System to enumerate CTC from 7.5 mL of venous blood. In this review we compare the outcomes from three prospective multicenter studies investigating the use of CTC to monitor patients undergoing treatment for metastatic breast (MBC), colorectal (MCRC), or prostate cancer (MPC) and review the CTC definition used in these studies. Evaluation of CTC at anytime during the course of disease allows assessment of patient prognosis and is predictive of overall survival.read more
Citations
More filters
Journal ArticleDOI
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
Emre Ozkumur,Ajay Shah,Jordan C. Ciciliano,Benjamin L. Emmink,David T. Miyamoto,Elena F. Brachtel,Min Yu,Min Yu,Pin-i Chen,Bailey Morgan,Julie Trautwein,Anya Kimura,Sudarshana Sengupta,Shannon L. Stott,Nezihi Murat Karabacak,Tom Barber,John R. Walsh,Kyle C. Smith,Philipp S. Spuhler,James P. Sullivan,Richard T. Lee,David T. Ting,Xi Luo,Xi Luo,Alice T. Shaw,Aditya Bardia,Lecia V. Sequist,David N. Louis,Shyamala Maheswaran,Ravi Kapur,Daniel A. Haber,Daniel A. Haber,Mehmet Toner +32 more
TL;DR: A multistage microfluidic device that is capable of sorting rare circulating tumor cells (CTCs) that are either positive or negative for the surface antigen epithelial cell adhesion molecule (EpCAM) and could be a promising addition to current diagnostic tools used in the clinic is developed.
Journal ArticleDOI
Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer
Matthew G Krebs,Robert Sloane,Lynsey Priest,Lee Lancashire,Jian-Mei Hou,Alastair Greystoke,Timothy H Ward,Roberta Ferraldeschi,Andrew Hughes,Glen Clack,Malcolm R Ranson,Caroline Dive,Fiona H Blackhall +12 more
TL;DR: CTCs are detectable in patients with stage IV NSCLC and are a novel prognostic factor for this disease, and further validation is warranted before routine clinical application.
Journal ArticleDOI
Size-selective collection of circulating tumor cells using Vortex technology
Elodie Sollier,Derek E. Go,James Che,Daniel R. Gossett,Sean O'Byrne,Westbrook M. Weaver,Nicolas Kummer,Matthew Rettig,Jonathan H. Goldman,Nicholas G. Nickols,Susan McCloskey,Rajan P. Kulkarni,Dino Di Carlo +12 more
TL;DR: This Vortex approach offers significant advantages over existing technologies, especially in terms of processing time, sample concentration, applicability to various cancer types, cell integrity and purity, and widespread adoption by clinicians and biologists who desire to enumerate CTCs.
Journal ArticleDOI
Circulating tumor cell technologies
TL;DR: As the understanding of CTC biology matures, CTC technologies will need to evolve, and some of the present challenges facing the field are discussed in light of recent data encompassing epithelial‐to‐mesenchymal transition, tumor‐initiating cells, and CTC clusters.
Journal ArticleDOI
Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
Matthew G Krebs,Jian-Mei Hou,Robert Sloane,Lee Lancashire,Lynsey Priest,Daisuke Nonaka,Timothy H Ward,Alison Backen,Glen Clack,Andrew Hughes,Andrew Hughes,Malcolm R Ranson,Fiona H Blackhall,Caroline Dive,Caroline Dive +14 more
TL;DR: In this paper, the authors compared an epithelial marker-dependent (CellSearch) and a marker-independent (isolation by size of epithelial tumor cells [ISET]) technology platform for the ability to identify CTCs.
References
More filters
Journal ArticleDOI
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited
TL;DR: It is now known that the potential of a tumour cell to metastasize depends on its interactions with the homeostatic factors that promote tumour-cell growth, survival, angiogenesis, invasion and metastasis.
Journal ArticleDOI
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli,G. Thomas Budd,Matthew J. Ellis,Alison Stopeck,Jeri Matera,M. Craig Miller,James M. Reuben,Gerald V. Doyle,W. Jeffrey Allard,Leon W.M.M. Terstappen,Daniel F. Hayes +10 more
TL;DR: The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
Journal ArticleDOI
Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Sunitha Nagrath,Lecia V. Sequist,Shyamala Maheswaran,Daphne W. Bell,Daphne W. Bell,Daniel Irimia,Lindsey Ulkus,Matthew R. Smith,Eunice L. Kwak,Subba R. Digumarthy,Alona Muzikansky,Paula D. Ryan,Ulysses J. Balis,Ulysses J. Balis,Ronald G. Tompkins,Daniel A. Haber,Mehmet Toner +16 more
TL;DR: The CTC-chip successfully identified CTCs in the peripheral blood of patients with metastatic lung, prostate, pancreatic, breast and colon cancer in 115 of 116 samples, with a range of 5–1,281CTCs per ml and approximately 50% purity.
Journal ArticleDOI
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.
W. Jeffrey Allard,Jeri Matera,M. Craig Miller,Madeline Repollet,Mark Connelly,Chandra Rao,Arjan G.J. Tibbe,Jonathan W. Uhr,Leon W.M.M. Terstappen +8 more
TL;DR: The CellSearch system can be standardized across multiple laboratories and may be used to determine the clinical utility of CTCs, which are extremely rare in healthy subjects and patients with nonmalignant diseases but present in various metastatic carcinomas with a wide range of frequencies.
Journal ArticleDOI
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono,Howard I. Scher,R. Bruce Montgomery,Chris Parker,M. Craig Miller,H. Tissing,Gerald V. Doyle,Leon W.W.M. Terstappen,Kenneth J. Pienta,Derek Raghavan +9 more
TL;DR: CTC are the most accurate and independent predictor of OS in CRPC, and this data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.